A recent report suggested that knockdown of CHD4 or its mutations (R975H or R1162W) is implemented with increased expressions of TGFB1 and CD133 (cancer stem cell marker), followed by the progression of uterine (endometrial) cancer. This evidence concerns the gene CHD4 and endometrial cancer.